Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are just fine, thank you, despite gray skies hovering over the Pharmalot campus. Despite the looming rain, our spirits remain sunny. As the Morning Mayor taught us long ago: Every new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will fire up the coffee kettle for another needed cup of stimulation. Our choice today is glazed doughnut. Yum. Meanwhile, here are a few choice items of interest we have assembled for you. Hope your journey is smooth, and do stay in touch. …

Since the controversial approval of the Alzheimer’s drug Aduhelm, both the Food and Drug Administration and Biogen (BIIB) have made an interesting argument: that approving the medicine will speed the development of other Alzheimer’s treatments, whatever one thinks of this medicine’s efficacy. Call it the “Field of Dreams” theory of drug development: If the FDA approves some medicines, more will be invented. But is this really true, STAT asks. Here’s what everyone agrees on: money.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment